RxDoctor Payments Data

John Morgan, MD

Ophthalmology · Atlanta, GANPI 1396206504

Payments from drug & device makers

$843in general payments, 2019–2025

Across 24 payments — averaging $35.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$364
  • Sight Sciences, Inc.$145
  • Bausch & Lomb Americas Inc.$123
  • Alcon$103
  • Harrow Eye, LLC$55
  • Dompe US, Inc.$28
  • plus $26 from 1 others

What the payments were for

  • Food & beverage$843100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$843 in reported general payments places this provider in the 30th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$63,467
Medicare patients
381
Services billed
772

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost68$39,556
RhopressaNetarsudil Mesylate40$18,467
Methazolamide62$14,400
CombiganBrimonidine Tartrate/Timolol29$12,788
Travoprost50$11,651
Brimonidine Tartrate308$11,572
RestasisCyclosporine11$10,992
RocklatanNetarsudil Mesylat/Latanoprost15$10,632
Brinzolamide32$8,672
Alphagan PBrimonidine Tartrate15$8,340
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat403$8,331
Latanoprost547$7,245
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$6,552
Prednisolone Acetate183$6,182
Dorzolamide-TimololDorzolamide/Timolol/Pf29$5,437

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$364$71,676123 claims
AlconSimbrinza$103$3,97213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →